Initiation of any tobacco and five tobacco products across 3 years among youth, young adults and adults in the USA: findings from the PATH Study Waves 1-3 (2013-2016).


Journal

Tobacco control
ISSN: 1468-3318
Titre abrégé: Tob Control
Pays: England
ID NLM: 9209612

Informations de publication

Date de publication:
05 2020
Historique:
received: 16 12 2019
revised: 07 02 2020
accepted: 10 02 2020
entrez: 24 4 2020
pubmed: 24 4 2020
medline: 3 6 2021
Statut: ppublish

Résumé

This study reports weighted cross-sectional prevalence of never use of tobacco, and longitudinal past 12-month (P12M), past 30-day (P30D) and frequent P30D any tobacco or specific tobacco product initiation across three 1-year waves. Longitudinal three-wave pathways are examined to outline pathways of exclusive and polytobacco initiation, as well as pathways of new initiators of electronic nicotine delivery systems (ENDS) or cigarettes. Data were drawn from the first three waves (2013-2016) of the Population Assessment of Tobacco and Health Study, a nationally representative, longitudinal cohort study of US youth and adults. Respondents with data at all three waves (youth, N = 11 046; young adults, N = 6478; adults 25+, N = 17 188) were included in longitudinal analyses. Across the three age groups, weighted cross-sectional analyses revealed never any tobacco use decreased each year from 2013 to 2016, reflecting overall increases in tobacco initiation in the population during this time. Compared with cigarettes, cigars, hookah and smokeless tobacco, ENDS had the highest proportion of P12M initiation from Wave 1 to Wave 3 (W3) for each age group. Among Initiation rates of ENDS among youth and young adults have increased the number of ever tobacco users in the US prevention strategies across the spectrum of tobacco products which can address youth initiation of tobacco products.

Identifiants

pubmed: 32321852
pii: tobaccocontrol-2019-055573
doi: 10.1136/tobaccocontrol-2019-055573
pmc: PMC7534279
mid: NIHMS1560860
doi:

Types de publication

Comparative Study Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

s178-s190

Subventions

Organisme : NIDA NIH HHS
ID : HHSN271201100027C
Pays : United States

Informations de copyright

© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: WMC reports long-term stock holdings in General Electric Company, 3M Company, and Pfizer Incorporated, unrelated to this manuscript. No financial disclosures were reported by the other authors of this paper.

Références

Tob Control. 2020 May;29(Suppl 3):s163-s169
pubmed: 32321850
Cancer Epidemiol Biomarkers Prev. 2017 May;26(5):748-755
pubmed: 28082346
Tob Control. 2020 May;29(Suppl 3):s155-s162
pubmed: 32321849
Nicotine Tob Res. 2018 Feb 7;20(3):312-320
pubmed: 28339616
Nicotine Tob Res. 2018 Aug 14;20(suppl_1):S5-S11
pubmed: 30125020
Ann Behav Med. 2017 Oct;51(5):730-740
pubmed: 28255935
Nicotine Tob Res. 2020 Apr 21;22(5):827-832
pubmed: 30371838
Nicotine Tob Res. 2018 Aug 14;20(suppl_1):S1-S4
pubmed: 30125021
JAMA. 2019 Dec 3;322(21):2095-2103
pubmed: 31688912
J Natl Cancer Inst. 2019 Oct 1;111(10):1088-1096
pubmed: 30689915
JAMA Pediatr. 2018 Feb 1;172(2):181-187
pubmed: 29297010
MMWR Morb Mortal Wkly Rep. 2016 Jul 15;65(27):685-91
pubmed: 27416365
Vital Health Stat 2. 1969 Jan;(31):1-24
pubmed: 5306564
Nicotine Tob Res. 2020 Apr 21;22(5):647-654
pubmed: 30820566
Tob Control. 2019 Jan;28(1):115-116
pubmed: 29669749
MMWR Morb Mortal Wkly Rep. 2017 Jun 16;66(23):597-603
pubmed: 28617771
Tob Control. 2019 Nov;28(6):603-609
pubmed: 30377241
Tob Control. 2019 Jan;28(1):42-49
pubmed: 29574448
Nicotine Tob Res. 2018 Aug 14;20(suppl_1):S88-S98
pubmed: 30125019
Pediatrics. 2018 Dec;142(6):
pubmed: 30397167
Nicotine Tob Res. 2019 Mar 30;21(4):458-468
pubmed: 29452385
JAMA Netw Open. 2019 Feb 1;2(2):e187794
pubmed: 30707232
MMWR Morb Mortal Wkly Rep. 2019 Feb 15;68(6):157-164
pubmed: 30763302
MMWR Morb Mortal Wkly Rep. 2018 Jun 08;67(22):629-633
pubmed: 29879097
Am J Prev Med. 2017 Jul;53(1):33-41
pubmed: 28169018
Tob Control. 2019 Nov;28(6):663-668
pubmed: 30297373
Tob Control. 2017 Jul;26(4):371-378
pubmed: 27507901
Tob Control. 2020 May;29(Suppl 3):s139-s146
pubmed: 32321847
Pediatrics. 2018 Jan;141(1):
pubmed: 29203523
Nicotine Tob Res. 2018 Aug 14;20(suppl_1):S39-S47
pubmed: 30125014
Pediatrics. 2016 Jul;138(1):
pubmed: 27296866
Tob Control. 2020 May;29(Suppl 3):s191-s202
pubmed: 32321853
Pediatrics. 2015 Mar;135(3):409-15
pubmed: 25647680
Pediatrics. 2018 Apr;141(4):
pubmed: 29507167
MMWR Morb Mortal Wkly Rep. 2018 Nov 09;67(44):1225-1232
pubmed: 30408019
Nicotine Tob Res. 2018 Aug 14;20(suppl_1):S22-S30
pubmed: 30125016
Int J Environ Res Public Health. 2018 Nov 09;15(11):
pubmed: 30423998
Tob Control. 2020 May;29(Suppl 3):s170-s177
pubmed: 32321851
Tob Control. 2020 May;29(Suppl 3):s147-s154
pubmed: 32321848
N Engl J Med. 2019 Jan 10;380(2):192-193
pubmed: 30554549
Nicotine Tob Res. 2018 Aug 14;20(suppl_1):S31-S38
pubmed: 30125023

Auteurs

Cassandra A Stanton (CA)

Behavioral Health and Health Policy Practice, Westat, Rockville, MD, United States cassandrastanton@westat.com.
Department of Oncology, Georgetown University Medical Center, Washington, DC, United States.

Eva Sharma (E)

Behavioral Health and Health Policy Practice, Westat, Rockville, MD, United States.

Elizabeth L Seaman (EL)

Behavioral Health and Health Policy Practice, Westat, Rockville, MD, United States.

Karin A Kasza (KA)

Department of Health Behavior, Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States.

Kathryn C Edwards (KC)

Behavioral Health and Health Policy Practice, Westat, Rockville, MD, United States.

Michael J Halenar (MJ)

Behavioral Health and Health Policy Practice, Westat, Rockville, MD, United States.

Kristie A Taylor (KA)

Behavioral Health and Health Policy Practice, Westat, Rockville, MD, United States.

Hannah Day (H)

Office of Science, Center for Tobacco Products, Food and Drug Administration, Silver Spring, MD, United States.

Gabriella Anic (G)

Office of Science, Center for Tobacco Products, Food and Drug Administration, Silver Spring, MD, United States.

Lynn C Hull (LC)

Office of Science, Center for Tobacco Products, Food and Drug Administration, Silver Spring, MD, United States.

Maansi Bansal-Travers (M)

Department of Health Behavior, Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States.

Jean Limpert (J)

Office of Science, Center for Tobacco Products, Food and Drug Administration, Silver Spring, MD, United States.

Lisa D Gardner (LD)

Office of Science, Center for Tobacco Products, Food and Drug Administration, Silver Spring, MD, United States.

Hoda T Hammad (HT)

Office of Science, Center for Tobacco Products, Food and Drug Administration, Silver Spring, MD, United States.

Nicolette Borek (N)

Office of Science, Center for Tobacco Products, Food and Drug Administration, Silver Spring, MD, United States.

Heather L Kimmel (HL)

National Institute on Drug Abuse, National Institutes of Health, Bethesda, MD, United States.

Wilson M Compton (WM)

National Institute on Drug Abuse, National Institutes of Health, Bethesda, MD, United States.

Andrew Hyland (A)

Department of Health Behavior, Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH